The outlook of companies tied to the drug's legacy presents a complex investment picture . While the initial surge generated substantial returns , generic alternatives have significantly diminished market share . Investing in connected pharmaceutical firms now requires a discerning assessment of proprietary rights , evolving patient changes, and th